Drug intelligence / Profile preview

UWD-01

Development stage: Preclinical
Lead developer: Wondercel Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

UWD-01 is an investigational allogeneic chimeric antigen receptor (CAR) T-cell therapy developed by Wondercel Therapeutics. It is engineered to target Guanylyl Cyclase C (GUCY2C), a cell surface protein frequently overexpressed in gastrointestinal malignancies, including colorectal, gastric, and esophageal cancers. As an allogeneic ("off-the-shelf") therapy, UWD-01 utilizes donor-derived T cells, potentially offering advantages in scalability and immediate availability compared to autologous CAR-T products. The therapy is currently in preclinical development for the treatment of GUCY2C-positive solid tumors.

Targets

GUCY2C (Guanylate cyclase C receptor)

Beyond the preview

Go deeper on UWD-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UWD-01.

Explore the full profile